View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Pitney Bowes Declares Common Stock Dividend

STAMFORD, Conn.--(BUSINESS WIRE)-- Pitney Bowes Inc. (NYSE:PBI), a global shipping and mailing company that provides technology, logistics, and financial services, today announced that its Board of Directors has declared a quarterly cash dividend on the company’s common stock of $0.05 per share. The dividend will be paid on June 7, 2024 to stockholders of record on May 23, 2024. About Pitney Bowes Pitney Bowes (NYSE:PBI) is a global shipping and mailing company that provides technology, logistics, and financial services to more than 90 percent of the Fortune 500. Small business, retail, en...

 PRESS RELEASE

EQS-News: MEDICLIN steigert Konzernumsatz und Betriebsergebnis im erst...

EQS-News: MEDICLIN AG / Schlagwort(e): Quartals-/Zwischenmitteilung MEDICLIN steigert Konzernumsatz und Betriebsergebnis im ersten Quartal 2024 02.05.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Offenburg, 2. Mai 2024 MEDICLIN steigert Konzernumsatz und Betriebsergebnis im ersten Quartal 2024 MEDICLIN steigert seinen Konzernumsatz für das erste Quartal 2024 um 4,9 % auf 185,4 Mio. Euro   Konzern-EBIT mit 4,1 Mio. Euro deutlich höher als im Vorjahreszeitraum (-1,7 Mio. Euro) Auslastung mit 85,1 % gegenüber Vorjahr ge...

 PRESS RELEASE

EQS-News: MEDICLIN increases consolidated sales and operating result i...

EQS-News: MEDICLIN AG / Key word(s): Quarterly / Interim Statement MEDICLIN increases consolidated sales and operating result in the first quarter of 2024 02.05.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Offenburg, 2 May 2024 MEDICLIN increases consolidated sales and operating result in the first quarter of 2024 MEDICLIN increases its consolidated sales for the first quarter of 2024 by 4.9% to EUR 185.4 million  Group EBIT of EUR 4.1 million significantly higher than in the same period of the previous year (EUR -1.7 m...

 PRESS RELEASE

Kimco Realty® Announces First Quarter 2024 Results

Kimco Realty® Announces First Quarter 2024 Results – Strong Growth and Leasing Activity – – Successful Execution on RPT Realty Acquisition – – Board Declares Quarterly Dividend – – Updates 2024 Outlook – JERICHO, N.Y., May 02, 2024 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM), a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States, today reported results for the first quarter ended March 31, 2024. For the three months ended March 31, 2024 and 2023, Kimco Realty’s n...

 PRESS RELEASE

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent ...

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – - Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – - Presented preclinical data at the 2024 Americ...

 PRESS RELEASE

Appian Announces First Quarter 2024 Financial Results

Appian Announces First Quarter 2024 Financial Results First quarter cloud subscription revenue increased 24% year-over-year to $86.6 million MCLEAN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2024. “Appian continues to push technological boundaries in our industry, from AI-backed services to process mining. Organizations globally are recognizing the power and simplicity of the Appian Platform,” said Matt Calkins, CEO & Founder. First Quarter 2024 Financial Highlights: Revenue: Cloud subscription ...

 PRESS RELEASE

Gilat to Participate in the 19th Annual Needham Technology, Media & Co...

Gilat to Participate in the 19th Annual Needham Technology, Media & Consumer Conference on May 15, 2024 PETAH TIKVA, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced management’s participation in the 19th Annual Needham Technology, Media and Consumer Conference at the Westin Grand Central Hotel in New York City. Mr. Adi Sfadia, the Company’s CEO, and Mr. Gil Benyamini, the Company’s CFO, will be available for one-on-one meetings with investors at the...

 PRESS RELEASE

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Fina...

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s discretion and subject to certain milestones, through March 31, 2026. The proceeds will be used ...

 PRESS RELEASE

Sotera Health Reports First-Quarter 2024 Results

Sotera Health Reports First-Quarter 2024 Results Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023Q1 2024 net income of $6 million or $0.02 per diluted share, compared to net income of $3 million or $0.01 per diluted share in Q1 2023Q1 2024 Adjusted EBITDA(1) increased 13.7% to $112 million, compared to Q1 2023Q1 2024 Adjusted EPS(1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of missi...

 PRESS RELEASE

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter ...

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial...

 PRESS RELEASE

Lithium Ionic Awarded Water Rights for Bandeira Lithium Project, Minas...

Lithium Ionic Awarded Water Rights for Bandeira Lithium Project, Minas Gerais, Brazil TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”), is pleased to report that it has received approval to draw water (“Water Rights”) from the local Piauí River for its 100%-owned Bandeira Lithium Project (“Bandeira”) in Minas Gerais, Brazil. The approval granting the right to use local water resources was granted on April 25, 2024, by the Minas Gerais Institute of Water Management (“Instituto Mineiro de Gestão das Águas” ...

 PRESS RELEASE

Kymera Therapeutics Announces First Quarter 2024 Financial Results and...

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into ...

 PRESS RELEASE

PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% A...

PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% Above Compressive Strength Target for Green Cement Additive Product Results surpass Portland Cement plus all traditional cement additive blends in pursuit of fly ash replacement in cement. MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. () (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address envi...

 PRESS RELEASE

Krystal Biotech to Present at the Association for Research in Vision a...

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington. Poster presentation details are as follows: Ti...

 PRESS RELEASE

Arvinas to Present at Upcoming Investor Conferences

Arvinas to Present at Upcoming Investor Conferences NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presen...

 PRESS RELEASE

Arqit and SoftIron Partner to sell more secure data center deployments

Arqit and SoftIron Partner to sell more secure data center deployments LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, and SoftIron, the worldwide leader in true private cloud infrastructure announce a partnership to enable customers to make a seamless migration to quantum safe cloud tasks, with a priority focus on the defense sector. Arqit’s quantum-safe products will be available as part of the SoftIron Partner Marketplace alongside other industry-leading solutions. SoftIron has integrated Arqit's Symmeti...

 PRESS RELEASE

Lee Enterprises reports second quarter Adjusted EBITDA growth and stro...

Lee Enterprises reports second quarter Adjusted EBITDA growth and strong digital growth Adjusted EBITDA(1) growth of 5% YOYDigital-only subscription revenue increased 48%(2) with subscriptions up 25%Total Digital Revenue(3) of $71M represented 48% of total revenue DAVENPORT, Iowa, May 02, 2024 (GLOBE NEWSWIRE) -- Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 73 markets, today reported preliminary second quarter fiscal 2024 financial results(4) for the peri...

 PRESS RELEASE

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of R...

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p

 PRESS RELEASE

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma to Participate in Upcoming May Conferences BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual The Citizens JMP Life Sciences ConferenceFormat: Fireside...

 PRESS RELEASE

Axogen, Inc Reports First Quarter 2024 Financial Results

Axogen, Inc Reports First Quarter 2024 Financial Results ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the sam...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch